Author

L. Farhat-Younis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. Gutwillig· 2 shared D. Rasoulouniriana· 2 shared N. Santana-Magal· 2 shared P. Rider· 2 shared Y. Carmi· 2 shared A. Ashkenazi· 1 shared A. Barzel· 1 shared A. Gleiberman· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Gutwillig

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivSep 30, 2023

Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity

Y. Carmi, L. Farhat-Younis, M. Na…·P. Rider

This study modifies myeloid cells to elicit tumor-specific cytotoxicity using chimeric receptors that signal through IgM and bind tumor antigens.

DOI 10.7554/elife.91999.3

mouseproteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintSep 10, 2020

Transient cell-in-cell formation underlies tumor resistance to immunotherapy

A. Gutwillig, N. Santana-Magal, L. Farhat-Younis…·Y. Carmi

This study identifies transient cell-in-cell formations as a mechanism enabling tumor resistance to immunotherapy, showing they protect tumor cells from immune and chemotherapy attacks.

DOI 10.1101/2020.09.10.287441

mousewhole-exome sequencing

𝕏 PostBluesky